Validating cancer drug targets

被引：108

作者：

Benson, John D. ^{[1
]}

Chen, Ying-Nan P. ^{[1
]}

Cornell-Kennon, Susan A. ^{[1
]}

Dorsch, Marion ^{[1
]}

Kim, Sunkyu ^{[1
]}

Leszczyniecka, Magdalena ^{[1
]}

Sellers, William R. ^{[1
]}

Lengauer, Christoph ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Cambridge, MA 02139 USA

来源：

NATURE | 2006年 / 441卷 / 7092期

关键词：

D O I：

10.1038/nature04873

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

引用

页码：451 / 456

页数：6

共 57 条

[1] Zebrafish as a cancer model system [J].

Amatruda, JF ;

Shepard, JL ;

Stern, HM ;

Zon, LI .

CANCER CELL, 2002, 1 (03) :229-231

[2] Proteasomal degradation of the Fox01 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins [J].

Aoki, M ;

Hao, J ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (37) :13613-13617

[3] The PIK3CA gene is mutated with high frequency in human breast cancers [J].

Bachman, KE ;

Argani, P ;

Samuels, Y ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Konishi, H ;

Karakas, B ;

Blair, BG ;

Lin, C ;

Peters, BA ;

Velculescu, VE ;

Park, BH .

CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775

[4] Raf: A strategic target for therapeutic development against cancer [J].

Beeram, M ;

Patnaik, A ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6771-6790

[5] Using Drosophila melanogaster to map human cancer pathways [J].

Brumby, AM ;

Richardson, HE .

NATURE REVIEWS CANCER, 2005, 5 (08) :626-639

[6] Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci [J].

Cool, M ;

Depault, F ;

Jolicoeur, P .

GENES CHROMOSOMES & CANCER, 2006, 45 (02) :191-202

[7] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[8] The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].

Deininger, M ;

Buchdunger, E ;

Druker, BJ .

BLOOD, 2005, 105 (07) :2640-2653

[9] Transgenic expression of PML/RAR alpha impairs myelopoiesis [J].

Early, E ;

Moore, MAS ;

Kakizuka, A ;

NasonBurchenal, K ;

Martin, P ;

Evans, RM ;

Dmitrovsky, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7900-7904

[10]

Emens Leisha A, 2005, Am J Ther, V12, P243

← 1 2 3 4 5 6 →